Analysis Of Income And Expense [Abstract]

Hyloris Pharmaceuticals SA - Filing #3166135

Concept 2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
Analysis of income and expense [abstract]
Revenue [abstract]
Revenue
2,087 EUR
900,000 EUR
Material income and expense [abstract]
Research and development expense
14,421 EUR
10,272 EUR
Miscellaneous other operating income
2,127 EUR
1,487 EUR
Miscellaneous other operating expense
- EUR
12,000 EUR
Selling, general and administrative expense [abstract]
General and administrative expense
5,546 EUR
3,517 EUR
Revenue and other operating income
4,214 EUR
2,387 EUR
Operating expense
20,207 EUR
14,024 EUR
Share of profit (loss) of associates and joint ventures accounted for using equity method [abstract]
Share of profit (loss) of associates and joint ventures accounted for using equity method
147,000 EUR
130,000 EUR
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income
15,380 EUR
15,380 EUR
10,770 EUR
10,770 EUR
11,906 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.